HENDERSON, NV--(Marketwired - Jun 2, 2017) - mCig Inc., ( OTCQB : MCIG ), a leading distributor of innovative products, technologies, and services for the global medical cannabis industry and Player's Network, Inc. ( OTCQB : PNTV ), a diversified holding company operating in media and marijuana, today announce the Phase 1 completion ofGreen Leaf Farms Holdings, facility in North Las Vegas.
Green Leaf Farms Holdings, LLC (Green Leaf), a subsidiary of PNTV, contracted mCig to develop and buildout their 27,000 sq. ft. facility in North Las Vegas. mCig completed the first Phase of development which included two vegetation and flower rooms, an extraction lab and all the needed infrastructure to support the facility. In addition, mCig worked with the City of North Las Vegas and the State of Nevada to ensure Green Leaf was 100% compliant. mCig has already completed the design, structural engineering and technical specifications for the remaining build out of the full 27,000 sq. ft. facility.
In addition to the completion of Phase 1, mCig is already nearing the completion of Phase 2 out of 3 total phases. Phase 2 is expected to complete in approx. 6 weeks which will add an additional 7,000 sq. ft. of cultivation to the facility.
PNTV Chief Executive Officer, Mark Bradley said, "Working with multiple government agencies and being fully compliant with so many rules and regulations has been very challenging! Working with mCig's management, specifically Ron Sassano and Robert Kressa, has made this process so much easier due to their invaluable industry expertise, know-how and experience in both construction and marijuana facility design."
"Green Leaf's facility is a state-of-the-art marijuana facility," said Paul Rosenberg, mCig's Chief Executive Officer. He continued, "The building has an amazing footprint with high ceilings and plenty of additional land that allows us to fully customize around optimizing growing marijuana and creating efficiencies with an ideal operation. We are looking forward to completing the next phase of development."
About Medical Cannabis Innovations Group ( OTCQB : MCIG )
Headquartered in Henderson, Nevada, mCig, Inc. ( OTCQB : MCIG ) is a diversified company servicing the legal cannabis, hemp and CBD markets via its lifestyle brands. mCig, Inc. is committed to being the leading distributor of technology, products, and services to fit the needs of a rapidly expanding industry. mCig, Inc. has transitioned from a vaporizer manufacturer to industry leading large scale, full service cannabis cultivation construction company with its Grow Contractors division currently operating in the rapidly expanding Nevada market.
mCig, Inc. also employs a world renowned tech team and has recently entered the tech space to satisfy its evolving role in technology and in keeping it's growing following up to speed.
The company looks forward to growing its core competencies to service the ancillary legal Cannabis, Hemp and CBD markets, with broader expansion to take place once federal laws change. With over seventy five years of experience combined between the key players that make up the Cannabis Grow Contractors Division, mCig Inc. is proud to work with Cannabis Industry leaders and provide broad and rounded solutions for legal growers nationwide.
About Player's Network, Inc. (PNTV)
Player's Network is a diversified company operating in media and cannabis markets. PNTV owns approximately 85% of Green Leaf Farms Holdings, LLC (Green Leaf Farms), which holds cultivation and production license(s) awarded by the state of Nevada. The cultivation license enables Green Leaf Farms to grow marijuana and the production license enables them to create extracts which are used for cartridges, oils and edibles. WeedTV.com is developing the ultimate resource for the marijuana lifestyle within our media operations.
For more information please visit www.PlayersNetwork.com
Please visit our Investor Relations site https://ir.playersnetwork.com
Sign up for PNTV investor alerts: https://ir.playersnetwork.com/investor-alerts
About Green Leaf Farms Holding, LLC
Green Leaf Holdings, LLC (Green Leaf Farms) produces medical and recreational cannabis products. Green Leaf is located in North Las Vegas, Nevada on 2.3 acres in a state-of-the-art 27,000 sq. ft. facility. They have a seasoned team of professional growers and operators to manage the facility with proven best practices to ensure they have the highest quality products available.
Read More

LOS ANGELES, CA--(Marketwired - Jun 1, 2017) - Endonovo Therapeutics, Inc. ( OTCQB :ENDV ) ("Endonovo" or the "Company"), a developer of non-invasive electroceuticals for the treatment of vascular diseases and inflammatory conditions in vital organs, today announced it is commencing a pre-clinical study at a contract research organization to assess the therapeutic potential of its Immunotronics™ platform in preventing and reversing inflammation and fibrosis in kidney disease. The study is the first of several currently planned studies targeting inflammatory pathologies of renal origin, including ischemia/reperfusion injury, acute kidney injury and diabetic nephropathy.
"We are excited to start our work on kidney disease and further expand our pipeline of non-invasive therapies targeting vascular diseases and inflammatory conditions in vital organs," commented Endonovo CEO, Alan Collier.
The Company's Immunotronics™ platform is a non-invasive electroceutical device that harnesses magnetically-induced electrical field pathways in cells and organs to illicit an anti-inflammatory response in tissues and organs.
"Several kidney diseases have a strong inflammatory component and our aim is to demonstrate the anti-inflammatory and anti-fibrotic properties of our non-invasive electroceutical technology. Reversing inflammation in the kidneys that can cause injury, fibrosis and ultimately end-stage renal disease would represent a truly game changing application of bioelectronic medicine," stated Mr. Collier.
"We not only believe that bioelectronic medicine is the future but that our non-invasive electromagnetic approach will be the standard for treating vital organs," concluded Mr. Collier.
About Kidney Disease:
More than 31 million people in the United States are currently living with chronic kidney disease (CKD), according to the American Kidney Fund. Diabetes and high blood pressure are the most common causes of kidney disease.
Chronic kidney disease means lasting damage to the kidneys that can get worse over time and in cases where the damage is severe, it can lead to kidney failure, also known as end-stage renal disease. If the kidneys fail the only option for patients is a kidney transplant or dialysis.
According to the National Institute of Diabetes and Digestive and Kidney Disease (NIDDK), the five-year survival rate for dialysis patients is only 35.8%, in comparison to a five-year survival rate of 85.5% for transplant patients.
However, there are currently 100,791 people waiting for a kidney transplant, according to the National Kidney Foundation. This severe donor kidney shortage means that the median wait time for a patient's first kidney transplant is 3.6 years.
On average, over 3,000 new patients are added to the kidney waiting list each month and 13 people die each day while waiting for a life-saving kidney transplant.
A significant rise in the pool of patients suffering from CKD, particularly the rising number of elderly people prone to a variety of diseases, such as diabetes, cardiovascular disorders and neurological conditions that affect the kidneys severely will grow the demand for CKD treatments.
The market for chronic kidney disease (CKD) drugs is estimated to reach $15.8 billion by 2024, according to Transparency Market Research.
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a leading developer of bioelectronic-applications in cell therapies and non-invasive electroceuticals. Endonovo's Immunotronics™ platform is dedicated to treating patients with life-threatening inflammatory conditions in vital organs using proprietary non-invasive electroceutical devices. The Company's non-invasive platform is based on magnetically-induced electrical field pathways that target the disruption of inflammation and cell death.
The Company's Cytotronics™ platform harnesses the bulk electrical properties of cells and tissues, namely magnetically-induced electrical field pathways to expand and enhance the therapeutic potential of cell therapies and produce next-generation biologics.
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
Investors: Sign Up for Email Alerts on Endonovo

PLEASANT HILL, CA / ACCESSWIRE / May 30, 2017 / Textmunication Holdings, Inc. (OTC PINK: TXHD) announces that it has entered into a settlement agreement with JSJ Investments Inc. with respect to litigation related to the conversion terms of a Note Payable.
To resolve the dispute, JSJ Investments has agreed to modify their note and remove the variable conversion price feature in exchange for a fixed conversion price. Under the terms of the amended note, Textmunication will honor the previously disputed conversion notice over-time subject to JSJ drawdown requests. Following the satisfaction of the disputed conversion, TXHD will issue an additional 138,939,277 shares in satisfaction of the remaining balance of the note - effectively removing the variable conversion of the note. Textmunication management feels this is beneficial to the company's share structure over the previous note which contained a variable conversion price.
"We are happy to put this litigation behind us, and we look forward working with all of our partners to maximize the value for our shareholders. We believe it's in the best interests of all parties and our shareholders to remove the variable rate component from the JSJ Note," said Textmunication CEO, Wais Asefi.
Text the keyword TXHD to 87365 to receive company announcements and alerts.
About Textmunication:
Textmunication is an online mobile SMS marketing platform service provider helping salons and fitness clubs communicate more effectively. Textmunication uses a non-intrusive, FCC-compliant text messaging medium to build loyalty, engage and retain members and generate new business. Salons and fitness centers across North America rely on the easy-to-use Textmunication dashboard to customize and automate text messages to select member groups and individuals so that they immediately receive the latest promotional offers, discounts, service alerts, events, training schedules and any other tailored content right to the palm of their hand.
Contact:
Textmunication Holdings, Inc.
Wais Asefi, CEO
1-800-677-7003
www.textmunication.com
Safe Harbor Statement
Except for the statements of historical fact contained herein, the information presented in this news release constitutes "forward-looking statements" made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned not to place undue reliance on any forward-looking statements in this press release as they reflect Textmunication Holdings' current expectations with respect to future events and are subject to risks and uncertainties that may cause actual results to differ materially from those contemplated. Potential risks and uncertainties include, but are not limited to, the risks described in Textmunication Holdings' filings with the Securities and Exchange Commission. Accordingly, readers should not place undue reliance on forward-looking statements contained in this news release and in any document referred to in this news release.
SOURCE: Textmunication Holdings, Inc.